What question did this study set out to answer?

To report the experiences of children with inhibitors in severe haemophilia B in the UK.

May 16, 2026

UK Experience of Children With Inhibitors in Severe Haemophilia B: A Report by the UKHCDO Paediatric Working Party

Key Points

To report the experiences of children with inhibitors in severe haemophilia B in the UK.
Data collected from multiple institutions in the UK regarding treatment outcomes and challenges.
Anonymised data available upon request for analysis.
Various conflicts of interest disclosed by contributors involved in advisories and grants.
Findings highlight the need for tailored treatment approaches due to the presence of inhibitors.

Abstract

Educational grants from Roche, SOBI; Honoraria from LFB, Roche/Chugai, SOBI; Advisory board Roche, SOBI. SubI: Octapharma, Sobi, Novo Nordisk, Roche, Sanofi, Takeda JA: Educational grants from Roche, Sobi; and honoraria from CSL, Sobi, Takeda, Novonordisk, Roche. TB: Honoraria from Bayer MM: Honoraria from Octapharma, Sobi; Educational grants from Sobi, Octapharma, Novo Nordisk; Consultancy: Sobi; PI/SI: Octapharma, Sobi, Novo Nordisk, Roche, Sanofi, Takeda SG: no conflicts of interest JP: Educational grants from Sobi, Novonordisk and BPL JM: Educational grants, speaker fees/honoraria from Roche, Sobi, CSL, Takeda, Bayer. SS: Educational grant CSL Behring JG: Educational grant SOBI, Roche/Chugai, Novonordisk; honoraria SOBI, Roche/Chugai, Novonordisk; Consultancy SOBI, Roche/Chugai, Novonordisk NB: no conflicts of interest. Data collected for presentation in this letter is available as an anonymised spreadheet if requested.

Bookmark

UK Experience of Children With Inhibitors in Severe Haemophilia B: A Report by the UKHCDO Paediatric Working Party

Key Points

Abstract

Cite This Study

Also Consider

Also Consider